BioArctic AB (publ) (BRCTF)
OTCMKTS
· Delayed Price · Currency is USD
19.34
0.00 (0.00%)
Jul 10, 2025, 4:00 PM EDT
BioArctic AB Revenue
BioArctic AB had revenue of 1.29B SEK in the quarter ending March 31, 2025, with 4,251.06% growth. This brings the company's revenue in the last twelve months to 1.52B, up 501.62% year-over-year. In the year 2024, BioArctic AB had annual revenue of 257.35M, down -58.22%.
Revenue (ttm)
1.52B SEK
Revenue Growth
+501.62%
P/S Ratio
11.31
Revenue / Employee
14.18M SEK
Employees
107
Market Cap
1.71B USD
Revenue Chart
* This company reports financials in SEK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 257.35M | -358.64M | -58.22% |
Dec 31, 2023 | 616.00M | 386.56M | 168.49% |
Dec 31, 2022 | 229.43M | 203.77M | 794.02% |
Dec 31, 2021 | 25.66M | -39.54M | -60.64% |
Dec 31, 2020 | 65.21M | -217.74M | -76.95% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
BioArctic AB News
- 16 days ago - BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize - PRNewsWire
- 4 weeks ago - BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review - PRNewsWire
- 5 weeks ago - BioArctic's Capital Markets Day 2025 - entering a new era of growth - PRNewsWire
- 2 months ago - Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 - March 2026) - PRNewsWire
- 2 months ago - Invitation to presentation of BioArctic's first quarter report for January - March 2025 on May 21 at 9.30 a.m. CET - PRNewsWire
- 2 months ago - Exidavnemab phase 2a study expanded to include MSA patients - PRNewsWire
- 3 months ago - The European Commission refers lecanemab decision to Appeal Committee - PRNewsWire
- 3 months ago - BioArctic's partner Eisai presents sales simulation for Leqembi® at its annual press conference - PRNewsWire